Compare BOSC & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | NOTV |
|---|---|---|
| Founded | 1990 | 1974 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 23.0M |
| IPO Year | 1996 | 1997 |
| Metric | BOSC | NOTV |
|---|---|---|
| Price | $4.87 | $0.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 59.5K | ★ 445.0K |
| Earning Date | 11-25-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | $48,333,000.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.49 |
| Revenue Next Year | N/A | $4.95 |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | ★ 19.49 | 4.54 |
| 52 Week Low | $3.30 | $0.47 |
| 52 Week High | $6.72 | $4.80 |
| Indicator | BOSC | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 38.26 |
| Support Level | $4.80 | $0.53 |
| Resistance Level | $5.16 | $0.59 |
| Average True Range (ATR) | 0.25 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 55.23 | 12.76 |
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.